Skip to main content

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Indications

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

You are now
leaving CIMERLI.com

Sandoz is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Sandoz policies.

Cancel Leave Site (opens in a new tab)

Please select which best describes you:

Healthcare Professional Patient or Caregiver

You are about to visit a website that contains clinical information created specifically for healthcare professionals.

If you are not a healthcare professional and would like to remain on the patient site, please click CANCEL.

Cancel Continue (opens in a new tab)